Allianz Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.89M | Sell |
23,600
-800
| -3% | -$66K | ﹤0.01% | 1572 |
|
|
2025
Q4 | $2.08M | Buy |
24,400
+5,000
| +26% | +$410K | ﹤0.01% | 1529 |
|
|
2025
Q3 | $1.51M | Buy |
19,400
+1,200
| +7% | +$93.8K | ﹤0.01% | 1605 |
|
|
2025
Q2 | $1.42M | Sell |
18,200
-15,200
| -46% | -$1.13M | ﹤0.01% | 1579 |
|
|
2025
Q1 | $2.42M | Buy |
33,400
+4,700
| +16% | +$336K | ﹤0.01% | 1426 |
|
|
2024
Q4 | $2.12M | Buy |
28,700
+3,800
| +15% | +$266K | ﹤0.01% | 1401 |
|
|
2024
Q3 | $1.64M | Sell |
24,900
-9,100
| -27% | -$661K | ﹤0.01% | 1482 |
|
|
2024
Q2 | $3.14M | Buy |
34,000
+29,800
| +710% | +$2.64M | ﹤0.01% | 1148 |
|
|
2024
Q1 | $401K | Sell |
4,200
-21,300
| -84% | -$1.79M | ﹤0.01% | 1690 |
|
|
2023
Q4 | $1.94M | Sell |
25,500
-21,600
| -46% | -$1.5M | ﹤0.01% | 1335 |
|
|
2023
Q3 | $3.26M | Buy |
47,100
+20,200
| +75% | +$1.62M | 0.01% | 1183 |
|
|
2023
Q2 | $2.54M | Buy |
26,900
+1,300
| +5% | +$113K | ﹤0.01% | 1173 |
|
|
2023
Q1 | $2.12M | Buy |
25,600
+17,000
| +198% | +$1.34M | ﹤0.01% | 1363 |
|
|
2022
Q4 | $642K | Buy |
8,600
+6,800
| +378% | +$524K | ﹤0.01% | 1651 |
|
|
2022
Q3 | $149K | Sell |
1,800
-9,300
| -84% | -$895K | ﹤0.01% | 1650 |
|
|
2022
Q2 | $1.05M | Sell |
11,100
-3,600
| -24% | -$373K | ﹤0.01% | 1658 |
|
|
2022
Q1 | $1.73M | Sell |
14,700
-1,900
| -11% | -$213K | ﹤0.01% | 1639 |
|
|
2021
Q4 | $2.15M | Sell |
16,600
-3,300
| -17% | -$385K | ﹤0.01% | 1583 |
|
|
2021
Q3 | $2.25M | Buy |
19,900
+14,400
| +262% | +$1.64M | ﹤0.01% | 1617 |
|
|
2021
Q2 | $570K | Sell |
5,500
-10,300
| -65% | -$971K | ﹤0.01% | 1984 |
|
|
2021
Q1 | $1.32M | Buy |
+15,800
| New | +$1.34M | ﹤0.01% | 1549 |
|
|
2020
Q3 | – | Sell |
-71,100
| Closed | -$4.91M | – | 2038 |
|
|
2020
Q2 | $4.91M | Buy |
71,100
+27,300
| +62% | +$1.94M | 0.01% | 1224 |
|
|
2020
Q1 | $2.75M | Sell |
43,800
-53,100
| -55% | -$3.83M | ﹤0.01% | 1416 |
|
|
2019
Q4 | $7.54M | Sell |
96,900
-7,200
| -7% | -$562K | 0.01% | 1296 |
|
|
2019
Q3 | $7.63M | Buy |
104,100
+17,400
| +20% | +$1.22M | 0.01% | 1246 |
|
|
2019
Q2 | $5.34M | Sell |
86,700
-9,900
| -10% | -$599K | 0.01% | 1471 |
|
|
2019
Q1 | $6.16M | Sell |
96,600
-192,000
| -67% | -$11M | 0.01% | 1361 |
|
|
2018
Q4 | $14.7M | Sell |
288,600
-59,400
| -17% | -$3.01M | 0.02% | 891 |
|
|
2018
Q3 | $20.2M | Sell |
348,000
-58,500
| -14% | -$2.86M | 0.02% | 890 |
|
|
2018
Q2 | $19.7M | Buy |
406,500
+28,500
| +8% | +$1.33M | 0.02% | 896 |
|
|
2018
Q1 | $17.6M | Sell |
378,000
-525,000
| -58% | -$22.8M | 0.02% | 959 |
|
|
2017
Q4 | $33.9M | Buy |
903,000
+129,600
| +17% | +$4.76M | 0.03% | 718 |
|
|
2017
Q3 | $28.2M | Buy |
773,400
+223,500
| +41% | +$8.52M | 0.02% | 804 |
|
|
2017
Q2 | $21.7M | Buy |
549,900
+146,700
| +36% | +$5.35M | 0.02% | 925 |
|
|
2017
Q1 | $12.6M | Sell |
403,200
-658,200
| -62% | -$20.6M | 0.01% | 1232 |
|
|
2016
Q4 | $33.2M | Buy |
1,061,400
+455,700
| +75% | +$14.8M | 0.03% | 760 |
|
|
2016
Q3 | $24.3M | Buy |
605,700
+3,000
| +0.5% | +$113K | 0.02% | 855 |
|
|
2016
Q2 | $20M | Buy |
602,700
+340,200
| +130% | +$11.6M | 0.02% | 898 |
|
|
2016
Q1 | $7.72M | Buy |
262,500
+230,700
| +725% | +$6.37M | 0.01% | 1270 |
|
|
2015
Q4 | $837K | Buy |
+31,800
| New | +$826K | ﹤0.01% | 2047 |
|
Other funds holding EW
VCM
VPM
Allianz Asset Management's EW Position: Q1 2026 in Review
Allianz Asset Management reduced its Edwards Lifesciences (EW) stake by 10% in Q1 2026, selling an estimated $18.5M and leaving 1,968,211 shares worth $158M. The position accounts for 0.17% of the portfolio, ranked #118.
Allianz Asset Management first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $191M in Q4 2021. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Allianz Asset Management held 1,968,211 shares of Edwards Lifesciences worth $158M as of Q1 2026.
- Allianz Asset Management sold 224,059 Edwards Lifesciences shares in Q1 2026, an estimated $18.5M.
- Edwards Lifesciences made up 0.17% of Allianz Asset Management's portfolio in Q1 2026, its #118 holding.
- Allianz Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
- Allianz Asset Management's Edwards Lifesciences position peaked at $191M in Q4 2021.
- 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.